Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-01-13Clinical Trial Update: Frequency of Gastrointestinal and Hepatic Manifestations Among Patients with Multiple Sclerosis, a Clinical Hospital Based Study
This clinical trial update outlines a hospital-based study to determine the frequency of gastrointestinal and hepatic manifestations in pati…
-
CLINICAL_TRIALS other · 2025-01-10Clinical Trial Update: The DANCEREX Proof-of-Concept Study for Chronic Neurological Disorders [NA]
A clinical trial update indicating the DANCEREX proof-of-concept study for chronic neurological disorders, including multiple sclerosis, is …
-
CLINICAL_TRIALS trial_result · 2025-01-09Clinical Trial Update: Pilot Study for the Evaluation of the More Stamina in Persons With Multiple Sclerosis
A completed pilot trial evaluating a treatment called More Stamina for improving stamina in people with multiple sclerosis.
-
CLINICAL_TRIALS research · 2025-01-07Clinical Trial Update: Entire-body PET Scans for Multiple Sclerosis [EARLY_Phase 1]
An early-phase 1 trial evaluating the use of whole-body PET imaging for multiple sclerosis, currently recruiting.
-
EMA approval · 2025-01-06EMA Authorised: Tecfidera (dimethyl fumarate) — Biogen Netherlands B.V.
The EMA has authorised Tecfidera (dimethyl fumarate) for use in multiple sclerosis; the marketing authorisation holder is Biogen Netherlands…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-01-01Clinical Trial Update: Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System. [EARLY_Phase 1]
A Phase 1 trial evaluating universal CAR-T cells for refractory autoimmune diseases of the nervous system; the study is not yet recruiting.
-
CLINICAL_TRIALS research · 2024-12-30Clinical Trial Update: Retrospective Study on the Role of SCFA Modulation in Multiple Sclerosis
Clinical trial update describing a retrospective study investigating the role of short-chain fatty acid modulation in multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2024-12-27Clinical Trial Update: Anakinra for the Treatment of Chronically Inflamed White Matter Lesions in Multiple Sclerosis [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating anakinra for chronically inflamed white matter lesions in multiple sclerosis has completed, and result…
-
CLINICAL_TRIALS trial_result · 2024-12-27Clinical Trial Update: Exercise Booster Sessions in People With Multiple Sclerosis [NA]
This clinical trial update summarizes a completed study evaluating the effect of exercise booster sessions in people with multiple sclerosis…
-
FDA approval · 2024-12-26FDA Approved: TERIFLUNOMIDE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for the generic teriflunomide from Aurobindo Pharma Limited.
-
CLINICAL_TRIALS research · 2024-12-24Clinical Trial Update: Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)
Clinical and imaging cohort study in China (CLUE) recruiting to collect data on neuroinflammatory diseases, including Neuromyelitis optica s…
-
CLINICAL_TRIALS trial_result · 2024-12-24Clinical Trial Update: Functional Electrical Stimulation Cycling for Managing Mobility Disability in People with Multiple Sclerosis [NA]
The trial evaluating Functional Electrical Stimulation Cycling for mobility disability in people with multiple sclerosis has completed. The …
-
FDA approval · 2024-12-20FDA Approved: TERIFLUNOMIDE — Supplemental Application (Biocon Pharma Inc.)
The FDA approved Biocon Pharma Inc.'s supplemental application for a generic teriflunomide product, authorizing its marketing in the United …
-
CLINICAL_TRIALS trial_result · 2024-12-20Clinical Trial Update: The Effect of Hybrid Telerehabilitation-Based Structured Exercise Programs in Patients With Multiple Sclerosis [NA]
A completed clinical trial evaluating hybrid telerehabilitation-based structured exercise programs for people with Multiple Sclerosis.
-
CLINICAL_TRIALS research · 2024-12-20Clinical Trial Update: Multiple Sclerosis and the Effects of Ketogenic Diet Therapy [NA]
A clinical trial is evaluating ketogenic diet therapy for people with relapsing-remitting multiple sclerosis; the study is currently recruit…
-
FDA approval · 2024-12-19FDA Approved: FINGOLIMOD HYDROCHLORIDE — Supplemental Application (Accord Healthcare Inc.)
FDA approved a supplemental application for fingolimod hydrochloride by Accord Healthcare Inc., authorizing a generic version of this multip…
-
CLINICAL_TRIALS research · 2024-12-19Clinical Trial Update: The NRC Dataset. Developing a Minimum Dataset for Multidisciplinary Rehabilitation: a Modified E-Delphi Study
A clinical trial update describing a modified E-Delphi study to develop a minimum dataset for multidisciplinary rehabilitation.
-
FDA approval · 2024-12-18FDA Approved: DIMETHYL FUMARATE — Supplemental Application (SOLA Pharmaceuticals, LLC)
FDA approved a supplemental application for dimethyl fumarate from SOLA Pharmaceuticals, LLC, granting approval for its generic product unde…
-
FDA approval · 2024-12-17FDA Approved: FINGOLIMOD — Supplemental Application (Solco Healthcare US, LLC)
FDA approved Solco Healthcare US, LLC's supplemental application for fingolimod (generic), authorizing a generic product under ANDA208003 fo…
-
FDA approval · 2024-12-17FDA Approved: DIMETHYL FUMARATE — Supplemental Application (Upsher-Smith Laboratories, LLC)
FDA approved Upsher-Smith Laboratories, LLC's supplemental application for Dimethyl Fumarate (generic), enabling market entry of a generic f…
-
FDA approval · 2024-12-17FDA Approved: TIZANIDINE — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application from Apotex Corp. for Tizanidine (generic), authorizing changes to the approved ANDA product.
-
CLINICAL_TRIALS trial_result · 2024-12-17Clinical Trial Update: HFS (High-Fiber Supplement) in MS (Multiple Sclerosis) [Phase 1, Phase 2]
A completed Phase 1/2 trial evaluating a High-Fiber Supplement in individuals with Multiple Sclerosis, with results posted on 2024-12-17.
-
FDA approval · 2024-12-17FDA Approved: FINGOLIMOD — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for Fingolimod filed by Sun Pharmaceutical Industries, Inc. as a generic version of the multiple…
-
FDA approval · 2024-12-17FDA Approved: DIMETHYL FUMARATE — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for dimethyl fumarate from Aurobindo Pharma Limited. This approves a generic version of the MS t…
-
CLINICAL_TRIALS trial_result · 2024-12-17Clinical Trial Update: Real World Effectiveness, Persistence, Tolerability, and Safety of Ofatumumab in Clinical Practice
Real-world study evaluating the effectiveness, persistence, tolerability, and safety of ofatumumab in multiple sclerosis patients treated in…